Chongqing Zhifei Biological Products Co., Ltd. Class ASZSE: 300122

Chongqing Zhifei Biological Products Co: H1 2024 revenue and profit declined sharply, but R&D and market leadership continued

· Issued by Chongqing Zhifei Biological Products Co., Ltd. Class A

H1 2024 revenue fell 25.31% and net profit dropped 47.55% year-over-year due to lower product sales, but market share and R&D investment remained strong. The company completed a share buyback, expanded partnerships, and is focused on optimizing strategy and risk control for H2.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis